Effect of adalimumab on work productivity and indirect costs in moderate to severe Crohn's disease: a meta-analysis.

ABSTRACT:

Objective

To assess the effect of adalimumab on work productivity and indirect costs in patients with Crohn's disease (CD) using a meta-analysis of clinical trials.

Methods

Study-level results were pooled from all clinical trials of adalimumab for moderate to severe CD in which work productivity outcomes were evaluated. Work Productivity and Activity Impairment Questionnaire outcomes (absenteeism, presenteeism and total work productivity impairment [TWPI]) were extracted from adalimumab trials. Meta-analyses were used to estimate pooled averages and 95% CIs of one-year accumulated reductions in work productivity impairment with adalimumab. Pooled averages were multiplied by the 2008 United States national average annual salary ($44,101) to estimate per-patient indirect cost

SUBMITTER: Binion DG 

PROVIDER: S-EPMC3202356 | biostudies-literature | 2011 Sep

REPOSITORIES: biostudies-literature